1, 3-Butadiene, CML and the t(9:22) translocation: A reality check. (5th November 2015)

• Record Type: Journal Article
• Authors: Albertini, Richard J.; Carter, Elizabeth W.; Nicklas, Janice A.; Vacek, Pamela M.; Walker, Vernon E.
• Is Part Of: Chemico-biological interactions. Volume 241(2015)
• Page Start: 32
• Page End: 39
• Publication Date: 2015-11-05
• Subjects: t(9:22) -- BCR-ABL -- Radiation -- HL60 -- 1, 3-Butadiene -- CML; Biochemistry -- Periodicals; Toxicological chemistry -- Periodicals; Biochemistry -- Periodicals; Biologie moléculaire -- Périodiques; Biochimie -- Périodiques; Toxicologie biochimique -- Périodiques; 572
• DOI: 10.1016/j.cbi.2015.05.011
• Languages: English
• ISSNs: 0009-2797

Abstract

Highlights: The t(9:22) translocation (Philadelphia Chromosome) is required for CML. No other genetic changes are necessary. Ionizing radiation induces CML and this translocation in human cells in vitro . Does 1, 3-butadiene induce the translocation? Testing will provide a reality check on epidemiology. Abstract: Epidemiological studies of 1, 3-butadiene have suggest that exposures to humans are associated with chronic myeloid leukemia (CML). CML has a well-documented association with ionizing radiation, but reports of associations with chemical exposures have been questioned. Ionizing radiation is capable of inducing the requisite CML-associated t(9:22) translocation (Philadelphia chromosome) in appropriate cells in vitro but, thus far, chemicals have not shown this capacity. We have proposed that 1, 3-butadiene metabolites be so tested as a reality check on the epidemiological reports. In order to conduct reliable testing in this regard, it is essential that a positive control for induction be available. We have used ionizing radiation to develop such a control. Results described here demonstrate that this agent does in fact induce pathogenic t(9:22) translocations in a human myeloid cell line in vitro, but does so at low frequencies. Conditions that will be required for studies of 1, 3-butadiene are discussed.